GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (OTCPK:KKPCF) » Definitions » Cyclically Adjusted Revenue per Share

Kaken Pharmaceutical Co (Kaken Pharmaceutical Co) Cyclically Adjusted Revenue per Share : $20.77 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kaken Pharmaceutical Co's adjusted revenue per share for the three months ended in Dec. 2023 was $3.395. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $20.77 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Kaken Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kaken Pharmaceutical Co was 1.70% per year. The lowest was 0.90% per year. And the median was 1.00% per year.

As of today (2024-06-06), Kaken Pharmaceutical Co's current stock price is $22.30. Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $20.77. Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 1.07.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kaken Pharmaceutical Co was 2.99. The lowest was 1.34. And the median was 2.02.


Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 19.38 23.58 18.65 -

Kaken Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.65 19.23 19.89 20.77 -

Competitive Comparison of Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.



Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kaken Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.395/106.8000*106.8000
=3.395

Current CPI (Dec. 2023) = 106.8000.

Kaken Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 5.071 95.700 5.659
201406 4.986 98.000 5.434
201409 5.016 98.500 5.439
201412 5.341 97.900 5.827
201503 4.558 97.900 4.972
201506 5.392 98.400 5.852
201509 5.493 98.500 5.956
201512 6.044 98.100 6.580
201603 5.087 97.900 5.549
201606 6.015 98.100 6.548
201609 6.158 98.000 6.711
201612 5.577 98.400 6.053
201703 4.989 98.100 5.431
201706 5.513 98.500 5.978
201709 5.561 98.800 6.011
201712 5.936 99.400 6.378
201803 5.038 99.200 5.424
201806 5.443 99.200 5.860
201809 5.245 99.900 5.607
201812 5.624 99.700 6.025
201903 4.889 99.700 5.237
201906 5.209 99.800 5.574
201909 5.438 100.100 5.802
201912 5.884 100.500 6.253
202003 4.547 100.300 4.842
202006 4.316 99.900 4.614
202009 4.578 99.900 4.894
202012 5.092 99.300 5.477
202103 4.296 99.900 4.593
202106 4.375 99.500 4.696
202109 4.575 100.100 4.881
202112 4.446 100.100 4.744
202203 4.087 101.100 4.317
202206 3.593 101.800 3.769
202209 3.463 103.100 3.587
202212 3.709 104.100 3.805
202303 3.476 104.400 3.556
202306 3.426 105.200 3.478
202309 3.230 106.200 3.248
202312 3.395 106.800 3.395

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Kaken Pharmaceutical Co  (OTCPK:KKPCF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=22.30/20.77
=1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kaken Pharmaceutical Co was 2.99. The lowest was 1.34. And the median was 2.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co (Kaken Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (Kaken Pharmaceutical Co) Headlines

No Headlines